BRIEF-Palvella Therapeutics Publishes Results From Phase 2 Clinical Trial Of Qtorin In The Journal Of Vascular Anomalies

Reuters
01-10

Jan 10 (Reuters) - Palvella Therapeutics Inc :

* PALVELLA THERAPEUTICS ANNOUNCES PUBLICATION OF RESULTS FROM PHASE 2 CLINICAL TRIAL OF QTORIN™ 3.9% RAPAMYCIN ANHYDROUS GEL (QTORIN™ RAPAMYCIN) FOR THE TREATMENT OF MICROCYSTIC LYMPHATIC MALFORMATIONS IN THE JOURNAL OF VASCULAR ANOMALIES

* PALVELLA THERAPEUTICS INC - PHASE 3 TRIAL OF QTORIN RAPAMYCIN FOR MICROCYSTIC LMS WITH DATA EXPECTED Q1 2026

* PALVELLA THERAPEUTICS INC - QTORIN RAPAMYCIN WELL-TOLERATED WITH NO SERIOUS ADVERSE EVENTS

* PALVELLA THERAPEUTICS INC - 100% PARTICIPANTS SHOW IMPROVEMENT AFTER 12 WEEKS OF QTORIN RAPAMYCIN

Source text: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10